Chronic kidney disease (CKD) remains one of the most serious global health challenges, affecting millions of people and significantly increasing the risk of kidney failure, cardiovascular disease, hospitalization, and premature death. In a major development for kidney care, Bayer has announced new clinical findings showing that finerenone significantly reduces the risk of both kidney disease progression and major cardiovascular complications in patients with CKD.
The latest data were presented at the 63rd European Renal Association (ERA) Congress, highlighting finerenone’s potential to improve outcomes for a broader range of CKD patients, including those without diabetes.
Finerenone Demonstrates Significant Kidney Protection
According to Bayer, results from the pooled INFINITY analysis revealed that patients treated with finerenone experienced a 24% reduction in the risk of CKD progression, including the development of kidney failure, compared with patients receiving a placebo alongside standard care.
One of the most notable findings was that the benefits of finerenone were observed regardless of diabetes status. This suggests that the therapy could provide kidney protection across a wider CKD population, expanding its potential clinical impact beyond traditionally targeted patient groups.
Key Findings from the INFINITY Analysis
| Outcome | Result |
|---|---|
| Risk Reduction in CKD Progression | 24% |
| Impact on Kidney Failure | Significantly Lower Risk |
| Diabetes Requirement | Benefits Seen With and Without Diabetes |
| Treatment Type | Finerenone + Standard Care |
Improved Cardiovascular Outcomes
Beyond kidney protection, researchers also reported significant cardiovascular benefits. Patients receiving finerenone experienced fewer serious heart-related events compared to those receiving placebo.
The findings reinforce the strong connection between kidney and heart health. CKD patients often face elevated risks of cardiovascular complications, making treatments that address both conditions particularly valuable.
Cardiovascular Benefits Observed
| Benefit | Impact |
|---|---|
| Major Cardiovascular Events | Reduced |
| Heart-Related Complications | Lower Incidence |
| Overall Cardiovascular Protection | Improved Outcomes |
FIND-CKD Phase III Study Shows Positive Results
In addition to the INFINITY analysis, Bayer presented results from the Phase III FIND-CKD trial, which focused on patients with non-diabetic chronic kidney disease.
The study demonstrated that finerenone significantly slowed the decline in kidney function among participants. Researchers described the results as both statistically significant and clinically meaningful, further supporting the drug’s role in CKD management.
Notably, the findings were published simultaneously in the prestigious New England Journal of Medicine, adding further credibility to the research.
FIND-CKD Trial Highlights
| Study Aspect | Details |
|---|---|
| Trial Name | FIND-CKD |
| Study Phase | Phase III |
| Patient Group | Non-Diabetic CKD Patients |
| Primary Outcome | Slower Kidney Function Decline |
| Significance | Statistically and Clinically Meaningful |
Why These Findings Matter
Chronic kidney disease affects hundreds of millions of people globally and often progresses silently until severe complications occur. Even with current treatment options, many patients continue to experience worsening kidney function and heightened cardiovascular risks.
The latest results suggest that finerenone could become an increasingly important therapy by:
- Slowing kidney disease progression
- Reducing the risk of kidney failure
- Lowering cardiovascular complications
- Supporting both diabetic and non-diabetic CKD patients
- Improving long-term patient outcomes
Current Status of Finerenone
Finerenone is currently marketed by Bayer under the brand name Kerendia and has already received regulatory approvals in multiple countries for specific CKD-related indications.
The newly presented data may help support future regulatory reviews and potential expansion of the therapy’s approved uses, particularly among non-diabetic CKD patients.
Future Outlook
The growing body of evidence surrounding finerenone highlights its potential as a comprehensive treatment option that addresses both kidney and cardiovascular health. As researchers continue to explore its benefits across broader patient populations, the therapy could play a pivotal role in transforming CKD management.
For millions living with chronic kidney disease, these findings offer renewed hope for reducing the burden of kidney-related complications while simultaneously protecting heart health.
Conclusion
Bayer’s latest clinical data strengthen the case for finerenone as a breakthrough therapy in chronic kidney disease management. With a 24% reduction in CKD progression risk, significant cardiovascular benefits, and promising results in non-diabetic CKD patients, finerenone is emerging as a powerful treatment option for protecting both kidney and heart health. As further evaluations and regulatory reviews continue, the therapy may help improve outcomes for an even broader population of CKD patients worldwide.
Recommended Products
